Complaint argues HHS and CMS exceeded statutory authority; rule puts patient access, investment in future innovation, and America’s long-term biotechnology leadership at risk.WASHINGTON, DC & SAN DIEGO, CA & SAN FRANCISCO, CA - The Biotechnology Innovation Organization (BIO), Biocom, and California Life Sciences (CLS), today filed a complaint in the Northern District of California challenging a final rule from the Centers for Medicare & Medicaid Services (CMS): the Global Benchmark for Efficient Drug Pricing Model (GLOBE).The groups, which collectively represent more than one-third of America’s biotech companies, contend that CMS, in finalizing the GLOBE model, exceeded its statutory authority to test payment and service delivery models that address a defined population with deficits in care. GLOBE rewrites the Medicare statute to force American biotech innovators to rebate the difference between the price of certain Medicare Part B medicines in the US and government-controlled prices in 19 foreign countries, effectively importing foreign price controls. The groups also assert that GLOBE violates appropriations law and constitutional principles, including the separation of powers and non-delegation doctrines."Patients need policies that lower their prescription costs without jeopardizing access to new medicines today and in the future," said Joe Franklin, Chief Legal and Policy Officer, BIO. "By finalizing the GLOBE model, CMS crossed the limits Congress placed on its authority, and ultimately, put patients, innovators, and American competitiveness at risk. We cannot - and should not - import policies that leave Americans behind and threaten American leadership in global biotechnology."GLOBE fails to meaningfully address access and affordability challenges Americans face and will instead cause irreparable harm to the future of biomedical innovation and America’s most vulnerable patients waiting for cures. A January 2026 analysis found that just 0.3% of…
Read More